MARCH 3, 2022 San Antonio, TX – Privately held Bluegrass Vascular Technologies, a leading innovator and global manufacturer of lifesaving devices and methods based on the Inside-Out® vascular access procedure, today announced the closing of a $5.0 million financing in convertible promissory notes to a group of qualified investors, including new […]
Author: Ken Dropiewski
CIRCA SCIENTIFIC HAS RECEIVED FDA CLEARANCE FOR NEW ESOPHAGEAL TEMPERATURE PROBE THAT IS VISIBLE ON 3D CARDIAC MAPPING SYSTEMS
S-CATH™ M is the only rapid-response, high-density esophageal temperature probe that is visible on 3D cardiac mapping systems. ENGLEWOOD, Colo., March 3, 2022 /PRNewswire/ — CIRCA Scientific, Inc. announced today that its S-CATH™ M Esophageal Temperature Probe is now cleared for sale in the United States. The new S-CATH M Probe can be […]
Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Release Tablets for Treatment of Hypertension
ATHENS, Ga., March 3, 2022 /PRNewswire/ — Athena Bioscience, LLC announced plans for the commercial launch of Nexiclon XR, the only once-daily clonidine extended-release tablets indicated for treatment of hypertension.1 Athena acquired exclusive rights to commercialize the product from Tris Pharma, Inc. in February 2021. The launch is set for April 2022 in all 50 U.S. […]
Stereotaxis Reports 2021 Full Year Financial Results
ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021. “In 2021 we delivered significant revenue growth, drove a resurgence in adoption of […]
Valbiotis Announces Upcoming Organizational Changes of its Board of Directors
Anticipated departure of Jocelyn PINEAU, Chief Financial Officer and member of the Board of Directors, at June 30, 2022. Recruitment of a new senior Chief Financial Officer to support the development of Valbiotis as a major player in health nutrition. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/SME […]
H.I.G. Capital Expands BioHealth Team with Addition of Gwen Watanabe
Watanabe brings deep experience in healthcare and medical devices STAMFORD – March 2, 2022 – H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $47 billion of equity capital under management, is pleased to announce that Gwen Watanabe has joined the firm’s dedicated life-science investment affiliate, H.I.G. BioHealth Partners, […]
The Argos Cardiac Output Monitor Interface is Declared Compatible with Philips IntelliBridge, Enabling Seamless Data Transfer to Hospital Electronic Medical Record (EMR) systems
VALHALLA, N.Y., March 2, 2022 /PRNewswire/ — Retia Medical today announced that it received a Declaration of Compatibility from Philips for its Argos Cardiac Output Monitor to interface with Philips IntelliBridge system on the IntelliVue patient monitoring systems. The Argos Monitor is now a compatible and “supported device” for Philips IntelliVue Patient […]
DispatchHealth and The American College of Cardiology Announce Innovative Collaboration Focused on In-Home Cardiovascular Care
DENVER and WASHINGTON, March 2, 2022 /PRNewswire/ — DispatchHealth, the nation’s first comprehensive in-home high acuity medical provider, today announced its collaboration with The American College of Cardiology (ACC), a nonprofit professional medical society, to enhance the lives of cardiovascular disease patients. The first of its kind, the collaboration between DispatchHealth and ACC is designed to […]
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2022 it granted stock options to purchase an aggregate of 86,850 shares of common stock to eight new employees, whose employment commenced in February 2022, as a material inducement to […]



